08/23/2017

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium® for Hairy Cell Leukemia.

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium^® for Hairy Cell Leukemia. NCCN Guidelines are currently available as Version 1.2018. 

• Indication for Treatment and relapse criteria (HCL-2)
  • Indications for treatment and relapse criteria were revised based on the recent consensus guidelines for the diagnosis and management of patients with classical hairy cell leukemia (Blood 2017;129:553-560).
• "Rituximab, if unable to receive purine analog" was added as a treatment option for "< Complete response" after initial treatment and for relapsed/refractory therapy. (HCL-2)
• Hairy Cell Leukemia response criteria from “Grever MR, Abdel-Wahab O, Andritsos, et al. Consensus guidelines for the diagnosis and management of patients with classical hairy cell leukemia. Blood 2017;129:553-560” was added. (HCL-A)